The Court of International Trade rejected importer Retractable Technologies' bids for a temporary restraining order and preliminary injunction stopping the collection of Section 301 duties on its needles and syringes. However, in a decision made public Nov. 4, Judge Claire Kelly did stop liquidation of Retractable's entries during the course of the company's suit, which challenges the legality of a Section 301 rate hike on needles and syringes.
The Court of International Trade in a decision made public Nov. 4 enjoined the liquidation of importer Retractable Technologies' entries of syringes during the course of its challenge to the Office of the U.S. Trade Representative's Section 301 tariff hike on needles and syringes. However, Judge Claire Kelly rejected Retractable's bids for a temporary restraining order and preliminary injunction on the collection of Section 301 tariffs on needles and syringes, finding that Retractable failed to show it would suffer irreparable harm if the duties are collected. The judge added that the balance of equities and public interest both weigh against taking such action.
Sally Laing, former chief international trade counsel for Sen. Ron Wyden, D-Ore., and the Senate Finance Committee, returned to Akin, the firm announced. Laing rejoined the firm as an international trade partner after working in the Senate and also as assistant general counsel in the Office of the U.S. Trade Representative. She started her career as a summer associate, international trade associate and counsel at Akin.
The Court of International Trade on Oct. 28 denied importer Retractable Technologies' motion for a temporary restraining order and preliminary injunction against the collection of certain Section 301 tariffs, though the court granted the company's motion for a preliminary injunction enjoining liquidation of its entries during the course of litigation. Judge Claire Kelly issued the confidential decision, giving the parties until Nov. 1 to review any confidential information in the opinion (Retractable Technologies v. U.S., CIT # 24-00185).
If a reelected President Donald Trump uses the existing Section 301 tariffs program to hike tariffs on all Chinese goods by at least 60%, that's likely to survive a court challenge, said two law professors who spoke during a Washington International Trade Association webinar on the executive branch's ability to make deals and impose trade restrictions without congressional say-so.
Domestic steel producer Zekelman Industries filed a lawsuit on Oct. 21 in a Washington, D.C., federal court alleging that the Mexican government breached its 2019 agreement with the U.S. to slow imports of Mexican steel products. The company argued that Mexico's breach of the deal "has devastated the U.S. steel industry," forcing the company to close two plants due to the oversupply of cheap steel (Zekelman Industries v. United States, D.D.C. # 24-02992).
Trade Law Daily is providing readers with the top stories from last week, in case you missed them. All articles can be found by searching on the title or by clicking on the hyperlinked reference number.
The Office of the U.S. Trade Representative is seeking applications for people who can serve on dispute panels reviewing final determinations in antidumping or countervailing duty proceedings when the exporter is from Mexico or Canada. The service period will begin April 1 and run through March 31, 2026. Applications are due by Nov. 29.
The U.S. on Oct. 15 urged the Court of International Trade to dismiss a suit from importer Retractable Technologies challenging the recent 100% increase of Section 301 tariffs on needles and syringes from China. The government said the trade court lacks jurisdiction to "second-guess the President's findings" and discretion in telling the U.S. trade representative to modify the Section 301 action and that the company failed to state a claim on which relief could be provided (Retractable Technologies v. United States, CIT # 24-00185).
The Court of International Trade on Oct. 9 denied importer Retractable Technologies' motion to quash a prehearing deposition subpoena from the U.S. in the company's suit against the Office of the U.S. Trade Representative's 100% Section 301 rate hike on needles and syringes (Retractable Technologies v. U.S., CIT # 24-00185).